share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC ·  Aug 30 04:36

Summary by Futu AI

SciSparc Ltd., a clinical-stage pharmaceutical company, announced on August 29, 2024, that its collaboration with Clearmind Medicine Inc. has led to the publication of a patent application for a novel ketamine-based combination therapy. The therapy combines SciSparc's Palmitoylethanolamide (PEA) with Clearmind's psychedelic molecule, MEAI, targeting treatments for addictions, weight loss, and mental health disorders. The collaboration has resulted in thirteen patent filings with the U.S. Patent and Trademark Office and other global patent offices. The announcement comes after the FDA's 2019 approval of a ketamine derivative for treatment-resistant depression and major depressive disorder with suicidal behavior, under strict medical supervision. SciSparc's CEO, Oz Adler, emphasized the company's commitment to developing proprietary combinations with PEA to enhance effectiveness and minimize adverse effects. SciSparc is also engaged in drug development programs for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus, and owns a subsidiary selling hemp seed oil-based products on Amazon.com.
SciSparc Ltd., a clinical-stage pharmaceutical company, announced on August 29, 2024, that its collaboration with Clearmind Medicine Inc. has led to the publication of a patent application for a novel ketamine-based combination therapy. The therapy combines SciSparc's Palmitoylethanolamide (PEA) with Clearmind's psychedelic molecule, MEAI, targeting treatments for addictions, weight loss, and mental health disorders. The collaboration has resulted in thirteen patent filings with the U.S. Patent and Trademark Office and other global patent offices. The announcement comes after the FDA's 2019 approval of a ketamine derivative for treatment-resistant depression and major depressive disorder with suicidal behavior, under strict medical supervision. SciSparc's CEO, Oz Adler, emphasized the company's commitment to developing proprietary combinations with PEA to enhance effectiveness and minimize adverse effects. SciSparc is also engaged in drug development programs for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus, and owns a subsidiary selling hemp seed oil-based products on Amazon.com.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.